# A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)

> **NCT05433194** · PHASE1 · UNKNOWN · sponsor: **Suzhou Abogen Biosciences Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** ABO1009-DP

## Key facts

- **NCT ID:** NCT05433194
- **Lead sponsor:** Suzhou Abogen Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-22
- **Primary completion:** 2022-09-26
- **Final completion:** 2023-08-25
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05433194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05433194, "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05433194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*